Medical cannabis products are legal in the UK from today – in very limited circumstances. This could include products without marketing authorisation, if approved by a registered specialist in certain conditions.

A change in the law brought about in a few short months enables cannabis-based products for medicinal use in humans to be prescribed as a Schedule 2 drug – essentially drugs that can be legally prescribed but carry higher risks for potential abuse.

This could be a special medicinal product for use at the direction of a doctor on the General Medical Council’s specialist register; an investigational medicinal product without marketing authorisation for use in a clinical trial; or a medicinal product with a marketing authorisation.

Read full article
I'm already a subscriber

Freddie Dawson

Managing editor, news
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the ECigIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization